A study of Acalabrutinib suspension to evaluate relative bioavailability and proton-pump inhibitor effect in healthy volunteers

Trial Identifier:	D822FC00004
Sponsor:	AstraZeneca
Collaborator:	Acerta Pharma
NCTID::	NCT04435483
Start Date:	May 2020
Primary Completion Date:	June 2020
Condition:	Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	English version

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
United States of America, CA	Glendale, CA, United States of America, 91206

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.